TEM · Tempus AI, Inc.
$52.10
-2.19 (-4.03%)
At close · Aug 14
Market Cap
$9.85B
Shares
180.43M
Tempus AI, Inc. Earnings Call Transcripts
Every quarterly earnings call for Tempus AI, Inc. (TEM) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲25.3%
$165.97M
−$552.21M
'24 Q2
24-08-06
▲33%
$180.93M
−$75.84M
'24 Q3
24-11-04
·
$200.68M
−$13.01M
'24 Q4
25-01-13
▲75.4%
$255.74M
−$68.04M
'25 Q1
25-05-06
▲89.6%
$314.63M
−$42.84M
'25 Q2
25-08-08
▲84.7%
$334.21M
−$79.98M
'25 Q3
25-11-04
▲83%
$367.21M
−$54.17M
'25 Q4
26-01-12
▲36.1%
$348.12M
−$125.92M
'26 Q1
26-05-05
LATEST
▲21.6%
$382.49M
$5.64M
'26 Q2
26-07-30
Earnings call
FY26 · Q2
2026-07-30
Tempus Second Quarter 2026 Earnings Conference Call
Confident tone
Personalis acquisition (MRD)
Data and Apps / pharma deals
FDA approvals and ASP uplift
Revenue
$382.49M
▲ 21.6% YoY Diluted EPS
$0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Capital Markets Day
Investor event
2026-05-29
Tempus AI Investor Day
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Tempus AI, Inc. Q1 FY2026 Earnings Call
Confident tone
MRD / Reimbursement Constraints
Diagnostics / Oncology Growth
Data & Apps / Insights Business
Revenue
$348.12M
▲ 36.1% YoY Diluted EPS
$-0.71
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-03
Morgan Stanley Technology, Media & Telecom Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-01-12
Tempus AI, Inc. Q4 FY2025 Earnings Call
Confident tone
Data / Insights Business
Diagnostics Growth
MRD / Tumor-Naive Assay
Revenue
$367.21M*
▲ 83% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Tempus AI, Inc. Q3 FY2025 Earnings Call
Confident tone
Genomics volume growth
Data licensing / Insights business
Reimbursement for data and algorithms
Revenue
$334.21M
▲ 84.7% YoY Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-08
Tempus AI, Inc. Q2 FY2025 Earnings Call
Confident tone
Genomics/Oncology volume growth
AI algorithms and reimbursement
ASP and reimbursement dynamics
Revenue
$314.63M
▲ 89.6% YoY Diluted EPS
$-0.25
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Tempus AI, Inc. Q1 FY2025 Earnings Call
Confident tone
AZ-Pathos Foundation Model Deal
Data and Services / Insights Business
MRD / Minimal Residual Disease
Revenue
$255.74M
▲ 75.4% YoY Diluted EPS
$-0.40
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Tempus AI, Inc. Q4 FY2024 Earnings Call
Confident tone
Data and Services Business
Ambry Genetics Acquisition and Integration
Patient-Facing App and Multimodal Data
Revenue
$200.68M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Tempus AI, Inc. Q3 FY2024 Earnings Call
Confident tone
Ambry Genetics acquisition
MRD and reimbursement
Data and licensing business
Revenue
$180.93M
▲ 33% YoY Diluted EPS
$-0.46
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Tempus AI, Inc. Q2 FY2024 Earnings Call
Revenue
$165.97M
▲ 25.3% YoY Diluted EPS
$-6.86
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–12 of 12 earnings calls
Key facts
CIK
1717115
CUSIP
88023B103
13F (30d)
459 filings
455 filers
Visit website
Investor relations